Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraosseous vs. Intravenous Vancomycin Administration in Spine Surgery
NCT06748144Phase 3Not yet recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vancomycin in surgical site infection (SSI) (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoints: Change in Level of Systemic Vancomycin Concentration, Level of Vancomycin Concentration in Bone and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
vancomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT06748144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06748144.